October 14, 2026 
5 min read
Back to Blog
William Alden, MD, PhD | Medical Peptide & Fatty Acid Series
Growth Hormone and Pituitary Peptides
By William Alden, MD, PhD | Medical Peptide, Regenerative & Fatty Acid Series
The growth hormone axis spans FDA-approved hormone replacement and long-acting analogs on one end, and widely marketed but unapproved secretagogues on the other. I draw a firm line between the two because the safety validation, manufacturing standards, and regulatory oversight behind them are not equivalent. This post expands on approved GH and GHRH agents, somatostatin analogs, IGF-1 therapy, and the secretagogue landscape, including 2026 compounding reclassifications.
Key Agents in This Class
Somatropin and long-acting analogs (somapacitan, lonapegsomatropin, somatrogon).
Recombinant human growth hormone and engineered long-acting forms (albumin-binding, TransCon prodrug, or fusion proteins) for once-weekly dosing. Approved for pediatric and adult GH deficiency and selected other indications. They directly activate GH receptors, stimulating IGF-1 production, protein synthesis, lipolysis, and linear growth.
Tesamorelin, sermorelin, macimorelin.
GHRH-axis agents. Tesamorelin is the only FDA-approved GHRH analog, indicated for reducing visceral adipose tissue in HIV-associated lipodystrophy. Sermorelin (29-amino-acid GHRH fragment) was previously approved but is now commonly compounded. Macimorelin is an oral ghrelin mimetic approved as a diagnostic for adult GH deficiency.
Octreotide, lanreotide, pasireotide.
Somatostatin analogs that bind sst receptors to suppress GH, glucagon, insulin, and tumor hormone secretion. Used in acromegaly and neuroendocrine tumors. Pasireotide has a broader receptor profile (sst1–5) and is useful in Cushing disease and refractory acromegaly.
Pegvisomant and mecasermin. Pegvisomant is a pegylated GH-receptor antagonist that lowers IGF-1 in acromegaly. Mecasermin is recombinant IGF-1 used when GH signaling is defective (e.g., Laron syndrome).
Secretagogues (ipamorelin, CJC-1295, GHRP-2, GHRP-6, hexarelin, AOD-9604, MK-677).
These agents raise GH via GHS-R1a (ghrelin receptor) or modified GHRH pathways. Ipamorelin and CJC-1295 (no DAC) have been treated as Category 1 for compounding in some periods; CJC-1295 with DAC, GHRP-2, and GHRP-6 have carried Category 2 restrictions due to safety concerns (sustained non-pulsatile stimulation, cortisol/prolactin elevation). AOD-9604 (GH fragment 176–191) targets lipolysis without IGF-1 elevation. MK-677 is an oral non-peptide secretagogue and is not a peptide drug.
Evidence and Regulatory Status
Approved agents have defined indications, established dosing, and safety monitoring requirements (including IGF-1 levels, glucose, and pituitary imaging where relevant). Secretagogues lack FDA approval for therapeutic use, rest largely on limited or non-US data, and occupy evolving compounding categories. The April 2026 FDA actions further clarified that removal from Category 2 does not automatically authorize compounding. Patients deserve clear communication about which category any given peptide occupies.
Frequently Asked Questions
Do peptides like CJC-1295 or ipamorelin safely boost growth hormone?
They raise GH in studies and can preserve a more physiologic pulsatile pattern than continuous GH administration, but they are not FDA-approved for this purpose and do not carry the long-term safety validation of approved GH or GHRH therapy.
What is the difference between CJC-1295 with and without DAC?
Without DAC the analog has a shorter half-life that supports pulsatile release when combined with a GHRP. With DAC (Drug Affinity Complex) it binds albumin and produces prolonged, relatively continuous GH elevation, which has raised regulatory safety concerns.
Is MK-677 a peptide?
No. It is an orally active non-peptide ghrelin mimetic. It is included for completeness but is investigational and not FDA-approved.
Clinical Perspective
Used within approved indications, these are precise endocrine tools. Outside those indications, the honest framing is that enthusiasm has often outrun regulatory approval and robust human outcome data. Caution, lawful sourcing, and transparent discussion of evidence gaps remain essential.
About the Author
William “Wes” Alden, MD, PhD, is a physician-scientist and internist whose career spans academic medicine, federal clinical research, community healthcare, and medical philanthropy. His work sits at the intersection of laboratory science and bedside care, and his writing consistently returns to one theme: regenerative and metabolic therapies deserve both open-minded use and rigorous scientific and regulatory scrutiny. This series surveys the major categories of therapeutic peptides and healthful fatty acids, one blog at a time, with an emphasis on honest evidence and clear regulatory status.
Important Disclosure and Disclaimer
This content is for general education and reflects Dr. Alden’s professional perspective. It is not medical advice and does not create a doctor-patient relationship. Individual results vary, and many agents discussed are not FDA-approved for the uses described. Several peptides are not FDA-approved and have an evolving federal compounding status; products labeled for research use only are never appropriate for use in people. Most fatty acids discussed are foods or dietary supplements and are not FDA-approved to treat any condition.
Any peptide or compounded agent should be used only through a licensed provider, with appropriately sourced pharmaceutical-grade material. Readers should consult a qualified healthcare professional about their own situation before pursuing any treatment.
Educational content reflecting Dr. Alden’s professional perspective. Not medical advice. Several agents named are not FDA-approved and some have an evolving compounding status. See the full disclosure accompanying this series.
